Iovance Biotherapeutics
IOVA
219 hedge funds and large institutions have $1.44B invested in Iovance Biotherapeutics in 2023 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 91 increasing their positions, 65 reducing their positions, and 39 closing their positions.
85% more call options, than puts
Call options by funds: $10.9M | Put options by funds: $5.88M
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
40% more repeat investments, than reductions
Existing positions increased: 91 | Existing positions reduced: 65
14% more capital invested
Capital invested by funds: $1.25B → $1.44B (+$181M)
0.67% less ownership
Funds ownership: 91.54% → 90.88% (-0.67%)
4% less funds holding
Funds holding: 228 → 219 (-9)
21% less first-time investments, than exits
New positions opened: 31 | Existing positions closed: 39
Top Buyers
Top Sellers
| 1 |
Morgan Stanley
New York
|
-$30M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$19.2M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$15.3M |
| 4 |
DM
Deerfield Management
New York
|
-$11.2M |
| 5 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
-$11M |
IOVA Hedge Fund Activity: Q2 2023 in Review
219 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Iovance Biotherapeutics (IOVA) for Q2 2023, worth a combined $1.44B — up 14% from $1.25B a quarter earlier.
Sellers outnumbered buyers: 39 funds closed out of IOVA and 31 opened new positions — a net loss of 8 holders — while 65 trimmed existing stakes and 91 added.
The largest buyer was Vanguard Group, adding an estimated $49.1M. The largest seller was Morgan Stanley, cutting an estimated $30M.
- 219 institutional investors held Iovance Biotherapeutics (IOVA) as of Q2 2023, down from 228 in Q1 2023.
- Funds reported $1.44B of Iovance Biotherapeutics stock for Q2 2023, up 14% quarter-over-quarter.
- 31 funds opened new Iovance Biotherapeutics positions in Q2 2023 and 39 closed out, a net change of -8 holders.
- The largest Iovance Biotherapeutics buyer in Q2 2023 was Vanguard Group, an estimated $49.1M added.
- The largest Iovance Biotherapeutics seller in Q2 2023 was Morgan Stanley, an estimated $30M sold.
Based on aggregated 13F filings for Q2 2023.